摘要
目的:建立大鼠体内落新妇苷的SPE-HPLC分析方法,通过复方银屑灵与单味土茯苓中落新妇苷药代动力学参数的比较,探讨配伍对落新妇苷大鼠体内药代动力学行为的影响。方法:雄性SD大鼠分别灌胃银屑灵、土茯苓提取物后,于不同时间眼眶静脉丛采血,固相萃取(SPE)法处理。采用反相高效液相色谱法,以甲醇-乙腈-0.05%甲酸为流动相梯度洗脱;Phenomenex C18色谱柱,柱温24℃,流速0.8 mL.min-1。结果:落新妇苷在0.266～53.1 mg.L-1线性关系良好(r=0.996);提取回收率为79.0%～89.1%;用非隔室模型估算药物动力学参数t1/2,Cmax,AUC0-t,AUC0-∞,MRT,各参数具有统计学意义。结论:该法可用于落新妇苷的药代动力学研究;配伍可提高落新妇苷在大鼠体内的生物利用度。
Objective： To establish a SPE-HPLC method for analyzing astilbin in rats serum and explore the effects of Yinxiel- ing（YXL） prescription and Smilacis Glabrae Rhizoma on the pharmacokinetic characteristics of effective components. Method： Male Sprague-dawley rats were administrated YXL and Smilacis Glabrae Rhizoma respectively. At different time points, serum concentration of astilbin was extracted by Solid Phase Extraction （SPE）and determined using HPLC method. Chromatographic separation was achieved on a reversed-phase Phenomenex Cls column with the mobile phase of methanol-acetonitrile-formic acid water soluiion（O. 05% formic acid）and gradient elution, temperature of bar was 24℃ ,flow rate was 0.8 mL ·L^-1. Result： The method showed excellent linearity over the concentration range 0. 266-53. 1 mg ·L^-1 of astilbin （ r = 0. 996 ）. The extract recoveries were from 79.0% to 89.1%. Significant diffenerce in pharmacokinetic parameter of astilbin including t1/2,Cmax,AUC0-1,AUC0-∞,and MRT were obtained through non-compartment model after oral administration of YXL prescription comparing with Smilacis Glabrae Rhizoma. Conclusion： The method was applied to a pharmacokinetic study of astilbin. It indicated that the bioavailability of astilbin in YXL enhanced in rats and one of the reasons may be that components of prescription affect the pharmacokinetics of astilbin in viyo.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2012年第12期1859-1861,共3页
China Journal of Chinese Materia Medica
基金
广东省重点科技计划项目(2010A03010008)
广东省科技厅-广东省中医院联合专项(2011B032200009)
广东省平台建设项目(2011A08030004)
广东省自然科学基金项目(10251040701000001)
广州市科技计划项目(2010J-E031)
关键词
银屑灵
土茯苓
落新妇苷
药代动力学
Yinxieling
Smilacis Glabrae Rhizoma
astilbin
pharmacokinetics
